Nasdaq
$0.8849▲ 2.05%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $14.1MShares out 15.9M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
5- 10.9After-hours26.10.10 06:124Ownership#●●●
Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc. insider Jeremy R. Graff has filed a Form 4 report detailing changes in beneficial ownership of securities as of January 22, 2026. This filing serves as the official disclosure of the insider's equity transaction.…more
$0.8849+2.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.1Pre-market26.10.01 21:008-KKey event
Allarity Therapeutics, Inc.
Allarity Therapeutics has strengthened its clinical development of stenoparib by securing new patents for its proprietary Drug Response Predictor (DRP) technology and achieving CLIA certification for its in-house laboratory. The company is utilizing the DRP platform to optimize patient selection for a potential pivotal trial, aiming to advance the drug toward FDA approval.…more
$0.8849+2.05%vs prev closeView filingShare - 9.29Pre-market26.09.29 21:008-KKey event
Allarity Therapeutics, Inc.
Allarity Therapeutics announced the expansion of its in-house medical laboratory capabilities to include proteomics and cell line research. This expansion is intended to support deeper mechanism-of-action research for its lead drug candidate, stenoparib, and broaden the range of research services offered to external partners.…more
$0.8849+2.05%vs prev closeView filingShare
4 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.30Pre-market26.09.30 22:11#●●●#●●●#●●●
Allarity Therapeutics Advances DRP Technology and Patents to Support Stenoparib Development…more
Allarity Therapeutics is strengthening its proprietary Drug Response Predictor technology and patent portfolio to accelerate the clinical development of its lead drug candidate, stenoparib. These advancements aim to improve patient selection in clinical trials and expand potential external partnership opportunities.…more
$0.8849+2.05%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.28Pre-market26.09.28 21:00
●●●●●●●● ●●●●● ●●●●●●
Allarity Therapeutics has expanded its in-house laboratory capabilities to include proteomics and cell line research to support its drug development programs. This expansion aims to improve internal research efficiency and broaden the range of scientific services offered to external partners.…more
$0.8849+2.05%vs prev close - 9.11Pre-market26.09.11 21:00
●●●●●●●● ●●●●● ●●●●●●
Allarity Therapeutics has filed a registration statement for the initial public offering of Allarity Acquisition Corp., a newly formed SPAC sponsored by its subsidiary. This move represents a strategic capital allocation and does not impact the company's existing operational funding runway.…more
$0.8849+2.05%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report